Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection

Cancer

Volumn 118, Issue 20, 2012, Pages 4981-4990

  Malouf, Gabriel G ^a,b   Brugières, Laurence ^c   Le Deley, Marie Cécile ^d   Faivre, Sandrine ^a   Fabre, Monique ^e   Paradis, Valérie ^a   Aerts, Isabelle ^f   Le Tourneau, Christophe ^a   Dreyer, Chantal ^a   Branchereau, Sophie ^e   Belghiti, Jacques ^a   Raymond, Eric ^a  

^a BEAUJON HOSPITAL   (France)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e Kremlin Bicêtre Hospital   (France)

^f INSTITUT CURIE   (France)

Author keywords

epigenetic; fibrolamellar hepatocellular carcinoma; natural history; outcome; prognosis

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; EPIGENETICS; FEMALE; FOLLOW UP; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; L1 RETROTRANSPOSON GENE; LIVER CELL CARCINOMA; LIVER RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIXED FIBROLAMELLAR LIVER CELL CARCINOMA; MORTALITY; ONCOGENE; ONSET AGE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PURE FIBROLAMELLAR LIVER CELL CARCINOMA; PYROSEQUENCING; RAS ASSOCIATION DOMAIN FAMILY 1A GENE; SCHOOL CHILD; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHILD; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867330957     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27520     Document Type: Article

References (40)

1. Edmondson HA,. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child. 1956; 91: 168-186.
2. Ward SC, Waxman S,. Fibrolamellar carcinoma: a review with focus on genetics and comparison to other malignant primary liver tumors. Semin Liver Dis. 2011; 31: 61-70.
3. Trankenschuh W, Puls F, Christgen M, et al. Frequent and distinct aberrations of DNA methylation patterns in fibrolamellar carcinoma of the liver. PLoS One. 2010; 5: e13688.
4. Liu S, Chan KW, Wang B, Qiao L,. Fibrolamellar hepatocellular carcinoma. Am J Gastroenterol. 2009; 104: 2617-2624; quiz 2625.
5. Torbenson M,. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol. 2007; 14: 217-223.
6. Pinna AD, Iwatsuki S, Lee RG, et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology. 1997; 26: 877-883.
7. Stipa F, Yoon SS, Liau KH, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. 2006; 106: 1331-1338.
8. Tsilividis B, Huet E, Lubrano J, et al. Late supra-diaphragmatic lymph node recurrence following resection of a fibrolamellar hepatocarcinoma: an unusual case. Surg Radiol Anat. 2010; 32: 123-127.
9. Yang Y, Nagano H, Ota H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery. 2007; 141: 196-202.
10. Sakon M, Nagano H, Nakamori S, et al. Intrahepatic recurrences of hepatocellular carcinoma after hepatectomy: analysis based on tumor hemodynamics. Arch Surg. 2002; 137: 94-99.
11. Craig JR, Peters RL, Edmondson HA, Omata M,. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer. 1980; 46: 372-379.
12. Kakar S, Burgart LJ, Batts KP, Garcia J, Jain D, Ferrell LD,. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol. 2005; 18: 1417-1423.
13. Maniaci V, Davidson BR, Rolles K, et al. Fibrolamellar hepatocellular carcinoma: prolonged survival with multimodality therapy. Eur J Surg Oncol. 2009; 35: 617-621.
14. El-Serag HB, Davila JA,. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004; 39: 798-803.
15. Berman MA, Burnham JA, Sheahan DG,. Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol. 1988; 19: 784-794.
16. Saab S, Yao F,. Fibrolamellar hepatocellular carcinoma. Case reports and a review of the literature. Dig Dis Sci. 1996; 41: 1981-1985.
17. Okano A, Hajiro K, Takakuwa H, Kobashi Y,. Fibrolamellar carcinoma of the liver with a mixture of ordinary hepatocellular carcinoma: a case report. Am J Gastroenterol. 1998; 93: 1144-1145.
18. Chang YC, Dai YC, Chow NH,. Fibrolamellar hepatocellular carcinoma with a recurrence of classic hepatocellular carcinoma: a case report and review of Oriental cases. Hepatogastroenterology. 2003; 50: 1637-1640.
19. Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002; 20: 1527-1536.
20. Ahn JB, Chung WB, Maeda O, et al. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer. 2011; 117: 1847-1854.
21. Lee ES, Issa JP, Roberts DB, et al. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance. Clin Cancer Res. 2008; 14: 2664-2672.
22. Schagdarsurengin U, Wilkens L, Steinemann D, et al. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene. 2003; 22: 1866-1871.
23. El-Gazzaz G, Wong W, El-Hadary MK, et al. Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma. Transpl Int. 2000; 13 (suppl 1): S406-S409.
24. Moreno-Luna LE, Arrieta O, Garcia-Leiva J, et al. Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma. BMC Cancer. 2005; 5: 142.
25. Gemer O, Segal S, Zohav E,. Pregnancy in a patient with fibrolamellar hepatocellular carcinoma. Arch Gynecol Obstet. 1994; 255: 211-212.
26. Louie-Johnsun M, Hewitt P, Perera DS, Morris DL,. Fibrolamellar hepatocellular carcinoma in pregnancy. HPB (Oxford). 2003; 5: 191-193.
27. Kroll D, Mazor M, Zirkin H, Schulman H, Glezerman M,. Fibrolamellar carcinoma of the liver in pregnancy. A case report. J Reprod Med. 1991; 36: 823-827.
28. Meriggi F, Forni E,. Surgical therapy of hepatic fibrolamellar carcinoma [in Italian]. Ann Ital Chir. 2007; 78: 53-58.
29. Agarwal VR, Takayama K, Van Wyk JJ, Sasano H, Simpson ER, Bulun SE,. Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma. J Clin Endocrinol Metab. 1998; 83: 1797-1800.
30. McCloskey JJ, Germain-Lee EL, Perman JA, Plotnick LP, Janoski AH,. Gynecomastia as a presenting sign of fibrolamellar carcinoma of the liver. Pediatrics. 1988; 82: 379-382.
31. Sher ES, Migeon CJ, Berkovitz GD,. Evaluation of boys with marked breast development at puberty. Clin Pediatr (Phila). 1998; 37: 367-371.
32. Hany MA, Betts DR, Schmugge M, et al. A childhood fibrolamellar hepatocellular carcinoma with increased aromatase activity and a near triploid karyotype. Med Pediatr Oncol. 1997; 28: 136-138.
33. Hemming AW, Langer B, Sheiner P, Greig PD, Taylor BR,. Aggressive surgical management of fibrolamellar hepatocellular carcinoma. J Gastrointest Surg. 1997; 1: 342-346.
34. Ringe B, Wittekind C, Weimann A, Tusch G, Pichlmayr R,. Results of hepatic resection and transplantation for fibrolamellar carcinoma. Surg Gynecol Obstet. 1992; 175: 299-305.
35. Poon RT, Fan ST, Lo CM, Liu CL, Wong J,. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg. 1999; 229: 216-222.
36. Bismuth H, Chiche L, Castaing D,. Surgical treatment of hepatocellular carcinomas in noncirrhotic liver: experience with 68 liver resections. World J Surg. 1995; 19: 35-41.
37. Kim MJ, White-Cross JA, Shen L, Issa JP, Rashid A,. Hypomethylation of long interspersed nuclear element-1 in hepatocellular carcinomas. Mod Pathol. 2009; 22: 442-449.
38. Schlitt HJ, Neipp M, Weimann A, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol. 1999; 17: 324-331.
39. Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol. 2003; 21: 421-427.
40. Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390.